Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hugh J Field

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Antiviral Research|July 18, 2006
Herpesvirus latency and therapy--from a veterinary perspectiveHugh J Field, Subhajit Biswas, Islam T Mohammad
Antiviral Research|March 8, 2008
Penciclovir is a potent inhibitor of feline herpesvirus-1 with susceptibility determined at the level of virus-encoded thymidine kinaseIslam T M Hussein, Rebecca V Menashy, Hugh J Field
The Journal of General Virology|May 1, 2009
A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structureSubhajit Biswas, Ricardo Núñez Miguel, Soumi Sukla, et al.
Antiviral Chemistry & Chemotherapy|September 8, 2006
Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile 2006 (1st edition)Erik De Clercq, Andrea Brancale, Anthony Vere Hodge, et al.
Antiviral Research|June 10, 2008
Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicitySubhajit Biswas, Laurence S Tiley, Holger Zimmermann, et al.
The Journal of Antimicrobial Chemotherapy|May 11, 2010
Mismatch primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitorSoumi Sukla, Subhajit Biswas, Alexander Birkmann, et al.
Archives of Virology|January 16, 2008
Substrate specificity and molecular modelling of the feline herpesvirus-1 thymidine kinaseIslam T M Hussein, Ricardo Núñez Miguel, Laurence S Tiley, et al.
Antiviral Chemistry & Chemotherapy|September 8, 2006
Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile 2006 (1st edition)Hugh J Field, Anthony Vere Hodge, Andrea Brancale, et al.
Antiviral Research|September 12, 2013
Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase-primase inhibitor pritelivirHugh J Field, Meei-Li Huang, Elizabeth M Lay, et al.
Antiviral Research|April 28, 2010
Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutantSoumi Sukla, Subhajit Biswas, Alexander Birkmann, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Antiviral Research|July 18, 2006
Herpesvirus latency and therapy--from a veterinary perspectiveHugh J Field, Subhajit Biswas, Islam T Mohammad
Antiviral Research|March 8, 2008
Penciclovir is a potent inhibitor of feline herpesvirus-1 with susceptibility determined at the level of virus-encoded thymidine kinaseIslam T M Hussein, Rebecca V Menashy, Hugh J Field
The Journal of General Virology|May 1, 2009
A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structureSubhajit Biswas, Ricardo Núñez Miguel, Soumi Sukla, et al.
Antiviral Chemistry & Chemotherapy|September 8, 2006
Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile 2006 (1st edition)Erik De Clercq, Andrea Brancale, Anthony Vere Hodge, et al.
Antiviral Research|June 10, 2008
Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicitySubhajit Biswas, Laurence S Tiley, Holger Zimmermann, et al.
The Journal of Antimicrobial Chemotherapy|May 11, 2010
Mismatch primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitorSoumi Sukla, Subhajit Biswas, Alexander Birkmann, et al.
Archives of Virology|January 16, 2008
Substrate specificity and molecular modelling of the feline herpesvirus-1 thymidine kinaseIslam T M Hussein, Ricardo Núñez Miguel, Laurence S Tiley, et al.
Antiviral Chemistry & Chemotherapy|September 8, 2006
Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile 2006 (1st edition)Hugh J Field, Anthony Vere Hodge, Andrea Brancale, et al.
Antiviral Research|September 12, 2013
Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase-primase inhibitor pritelivirHugh J Field, Meei-Li Huang, Elizabeth M Lay, et al.
Antiviral Research|April 28, 2010
Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutantSoumi Sukla, Subhajit Biswas, Alexander Birkmann, et al.
Pageof 4